Namenda is a drug owned by Allergan Sales Llc. It is protected by 2 US drug patents filed from 2013 to 2014 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 11, 2015. Details of Namenda's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5061703 (Pediatric) | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(9 years ago) |
Expired
|
| US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Namenda is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Namenda's family patents as well as insights into ongoing legal events on those patents.
Namenda's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Namenda's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 11, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Namenda Generic API suppliers:
Memantine Hydrochloride is the generic name for the brand Namenda. 35 different companies have already filed for the generic of Namenda, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Namenda's generic
How can I launch a generic of Namenda before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Namenda's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Namenda's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Namenda -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 5 mg and 10 mg | 16 Oct, 2007 | 14 | 30 Jan, 2015 | 11 Apr, 2015 | Eligible |
Alternative Brands for Namenda
Namenda which is used for managing moderate to severe dementia of the Alzheimer's type., has several other brand drugs in the same treatment category and using the same active ingredient (Memantine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Abbvie |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Memantine Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Memantine Hydrochloride, Namenda's active ingredient. Check the complete list of approved generic manufacturers for Namenda
About Namenda
Namenda is a drug owned by Allergan Sales Llc. It is used for managing moderate to severe dementia of the Alzheimer's type. Namenda uses Memantine Hydrochloride as an active ingredient. Namenda was launched by Allergan in 2005.
Approval Date:
Namenda was approved by FDA for market use on 18 April, 2005.
Active Ingredient:
Namenda uses Memantine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Memantine Hydrochloride ingredient
Treatment:
Namenda is used for managing moderate to severe dementia of the Alzheimer's type.
Dosage:
Namenda is available in solution form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 2MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | SOLUTION | Discontinued | ORAL |
Namenda is a drug owned by Abbvie Inc. It is protected by 2 US drug patents filed from 2013 to 2014 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 11, 2015. Details of Namenda's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5061703 (Pediatric) | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Oct, 2015
(9 years ago) |
Expired
|
| US5061703 | Adamantane derivatives in the prevention and treatment of cerebral ischemia |
Apr, 2015
(9 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Namenda is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Namenda's family patents as well as insights into ongoing legal events on those patents.
Namenda's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Namenda's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 11, 2015 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Namenda Generic API suppliers:
Memantine Hydrochloride is the generic name for the brand Namenda. 35 different companies have already filed for the generic of Namenda, with Aurobindo Pharma Ltd having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Namenda's generic
How can I launch a generic of Namenda before its drug patent expiration? :
You can seek FDA approval to launch a generic drug before the expiration of Namenda's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Namenda's sponsor is invalid, unenforceable, or will not be infringed by your generic product.
Given below are the details of the already filed Para IV certificates on Namenda -
| Strength | Submission Date | ANDA(s) Filed | First applicant approval | Last patent expiry | 180 day status |
|---|---|---|---|---|---|
| 5 mg and 10 mg | 16 Oct, 2007 | 14 | 30 Jan, 2015 | 11 Apr, 2015 | Eligible |
Alternative Brands for Namenda
Namenda which is used for managing moderate to severe dementia of the Alzheimer's type., has several other brand drugs in the same treatment category and using the same active ingredient (Memantine Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Abbvie |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Memantine Hydrochloride. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Abbvie |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Memantine Hydrochloride, Namenda's active ingredient. Check the complete list of approved generic manufacturers for Namenda
About Namenda
Namenda is a drug owned by Abbvie Inc. It is used for managing moderate to severe dementia of the Alzheimer's type. Namenda uses Memantine Hydrochloride as an active ingredient. Namenda was launched by Abbvie in 2003.
Approval Date:
Namenda was approved by FDA for market use on 16 October, 2003.
Active Ingredient:
Namenda uses Memantine Hydrochloride as the active ingredient. Check out other Drugs and Companies using Memantine Hydrochloride ingredient
Treatment:
Namenda is used for managing moderate to severe dementia of the Alzheimer's type.
Dosage:
Namenda is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 10MG | TABLET | Prescription | ORAL |
| 5MG | TABLET | Prescription | ORAL |